Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD

Yunus Çolak
European Respiratory Journal 2021 57: 2004008; DOI: 10.1183/13993003.04008-2020
Yunus Çolak
1Dept of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
2The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
3Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yunus.colak@regionh.dk yunuscol@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Acute exacerbations but not accelerated FEV1 decline is associated with increased cardiovascular comorbidity risk in patients with COPD https://bit.ly/36AuDV6

COPD is a prevalent disease in middle-aged and older adults associated with significant morbidity and mortality [1]. Individuals with COPD have an increased risk of different comorbidities, which complicates management of an already troublesome disease [2, 3]. One of these comorbidities is cardiovascular disease, which is believed to arise from shared risk factors, such as tobacco smoke, and the higher prevalence of major cardiovascular risk factors in individuals with COPD [4]. Nonetheless, even after accounting for all these risk factors, there remains an association between COPD and cardiovascular disease suspected to involve such diverse mechanisms as hypoxia and systemic inflammation [4].

It is now increasingly evident that airflow limitation in COPD develops gradually over many years from different lung function trajectories [5]. So far, we have been able to identify two of these lung function trajectories; that is, acceleration of the normal age-related decline of lung function due to exposure to noxious particles or gases such as tobacco smoke, and low maximally attained lung function in early adulthood [6–8]. However, lung function trajectories not only seem to have an importance for the development of airflow limitation in COPD but also prognosis and risk of comorbidities afterwards. Recently, it was shown that COPD developed through accelerated lung function decline is associated with a higher mortality rate compared to COPD developed through low maximally attained lung function in early adulthood [9]. In addition, low maximally attained lung function in early adulthood has been associated with development of cardiovascular and metabolic disease later in life [10]. An obvious question therefore arises: whether the linkage between COPD and comorbidities such as cardiovascular disease could partly be explained by pathogenic mechanisms responsible for airflow limitation?

In this issue of the European Respiratory Journal, Whittaker et al. [11] address the question whether accelerated lung function decline is associated with increased cardiovascular disease in patients with COPD from a primary care population in England. By using the Clinical Practice Research Datalink, an electronic healthcare database of a subset of general practitioners (contains 7% of the UK population), approximately 36 000 patients with COPD were included. Patients with COPD were initially followed for at least 3 years to estimate forced expiratory volume in the first second (FEV1) decline, and hereafter followed for up to 10 years to estimate risk of coronary heart disease, heart failure, myocardial infarction, stroke, atrial fibrillation and cardiovascular mortality. Accelerated FEV1 decline was defined as patients with the steepest quartile of the decline, corresponding to approximately >40 mL per year. During follow-up, more than 6000 patients developed or died due to cardiovascular disease. After a careful analytical approach, the investigators did not find evidence of an association between accelerated FEV1 decline and risk of cardiovascular disease or mortality in patients with COPD. Compared to patients with non-accelerated FEV1 decline, adjusted hazard ratio for composite cardiovascular disease was 0.98 (95% CI 0.90–1.06) in those with accelerated FEV1 decline. Corresponding hazard ratios were 1.02 (95% CI 0.87–1.19) for coronary heart disease, 0.99 (95% CI 0.83–1.20) for heart failure, 0.89 (95% CI 0.70–1.12) for myocardial infarction, 1.01 (95% CI 0.83–1.23) for stroke, 0.97 (95% CI 0.81–1.15) for atrial fibrillation and 0.94 (95% CI 0.71–1.25) for cardiovascular mortality, respectively.

These results are of considerable interest, as they illustrate for the first time that accelerated FEV1 decline, a major pathogenic mechanism in development of airflow limitation, is not associated with excess cardiovascular comorbidity risk in patients with COPD. Instead, Whittaker et al. [11] found that frequency and severity of acute exacerbations and increased breathlessness, as measured by the modified Medical Research Council Dyspnoea scale (mMRC), increased cardiovascular comorbidity risk independent from major risk factors. In fact, the risk estimates for acute exacerbations sometimes seemed higher than other traditional risk factors, including tobacco smoke, body mass index, diabetes and hypertension (tables E1–E7 in the supplementary material of [11]). While mMRC may be rather unspecific and could in principle be sign of underlying coronary artery disease, acute exacerbations have previously been associated with increased risk of cardiovascular disease [12, 13]. A post hoc analysis of the SUMMIT trial showed that risk of major cardiovascular disease events, including myocardial infarction, stroke and cardiovascular mortality, was substantially increased within 30 days from a subsequent acute exacerbation in patients with COPD and even persisted up to 90 days and to 1 year [14]. The risk was highest for those exacerbations requiring hospitalisation [14]. Similarly, in the UPLIFT trial, subsequent acute exacerbation increased risk of myocardial infarction and stroke [15]. Thus, there now seems to be substantial evidence to suggest that patients with COPD need to be followed closely for cardiac events following an acute exacerbation. But the real question is, can we prevent them and with which intervention? A potential mechanism that has been proposed includes elevated inflammatory biomarkers in blood during and after an acute exacerbation, thereby leading to systemic inflammation [14, 16, 17]. This could be plausible as systemic inflammation through the interleukin-6 signalling pathway has been causally linked to coronary heart disease [18, 19], and modulation of it with canakinumab seems to reduce cardiovascular event rates [20].

Interestingly, these results presented by Whittaker et al. [11] contrast with the recent findings in the Atherosclerosis Risk in Communities (ARIC) cohort, a general population sample from USA, where accelerated FEV1 decline was associated with increased risk of heart failure in approximately 10 000 individuals [21]. The reason for the discrepancy may be differences in study design, including length of follow-up time, cohorts from different time periods, and how endpoints were assessed. However, it may also be that the importance of the FEV1 decline differs before and after development of COPD. While accelerated FEV1 decline may increase risk of certain cardiovascular diseases in individuals without COPD, it probably has less importance in individuals with COPD and is overshadowed by other risk factors such as acute exacerbations. Unfortunately, Whittaker et al. [11] were unable to explore this association in individuals with normal spirometry.

Strengths of the present study include an impressive large primary care population of COPD patients with a long follow-up time on wide range of different cardiovascular diseases identified from valid sources. An important limitation, also acknowledged by the investigators, is that patients with COPD were required to have at least 3 years of follow-up to estimate FEV1 decline, which may lead to some form of immortal time bias, i.e. that patients had to survive until estimation of the decline before they could be included and were potentially “immortal” during this time period. Another limitation is that FEV1 decline was only determined for a very short time period, which would be more accurate if a longer time period was used instead. Another limitation is the lack of other important potential confounders such as tobacco consumption, plasma cholesterol, physical activity and alcohol consumption; however, it is reassuring to see that risk estimates were largely similar in unadjusted and adjusted analyses, suggesting a low impact of residual confounding. Risk estimates were also largely similar in extensive subgroup and sensitivity analyses, suggesting that results are likely robust and valid.

Comorbidities in COPD are often explained by shared risk factors, which therefore need to be considered, prioritised, handled and treated accordingly. However, shared risk factors do not completely explain the very high burden of comorbidities in COPD, where we sometimes need to use different, and often unconventional, ways to study and understand them. In recent years, we have started to focus again on the natural history of airflow limitation in order to understand COPD heterogeneity. Perhaps lung function trajectories can be extended beyond COPD to explain the interplay between health and disease [22]. With their study, Whittaker et al. [11] should be congratulated for helping us to understand cardiovascular comorbidity risk further in patients with COPD.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-04008-2020.Shareable

Footnotes

  • Conflict of interest: Y. Çolak reports personal fees from Boehringer Ingelheim, AstraZeneca and Sanofi Genzyme outside the submitted work.

  • Received October 29, 2020.
  • Accepted November 10, 2020.
  • Copyright ©ERS 2021
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Çolak Y,
    2. Afzal S,
    3. Nordestgaard BG, et al.
    Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med 2017; 5: 426–434. doi:10.1016/S2213-2600(17)30119-4
    OpenUrl
  2. ↵
    1. Divo M,
    2. Cote C,
    3. de Torres JP, et al.
    Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155–161. doi:10.1164/rccm.201201-0034OC
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Vanfleteren LE,
    2. Spruit MA,
    3. Groenen M, et al.
    Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728–735. doi:10.1164/rccm.201209-1665OC
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Rabe KF,
    2. Hurst JR,
    3. Suissa S
    . Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018; 27: 180057. doi:10.1183/16000617.0057-2018
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Agusti A,
    2. Hogg JC
    . Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med 2019; 381: 1248–1256. doi:10.1056/NEJMra1900475
    OpenUrlPubMed
  6. ↵
    1. Fletcher C,
    2. Peto R
    . The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645–1648. doi:10.1136/bmj.1.6077.1645
    OpenUrlAbstract/FREE Full Text
    1. Fletcher CM,
    2. Peto R,
    3. Tinker CM, et al.
    The natural history of chronic bronchitis and emphysema: an eight-year study of early chronic obstructive lung disease in working men in London. Oxford, Oxford University Press, 1976.
  7. ↵
    1. Lange P,
    2. Celli B,
    3. Agusti A, et al.
    Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015; 373: 111–122. doi:10.1056/NEJMoa1411532
    OpenUrlCrossRefPubMed
  8. ↵
    1. Marott JL,
    2. Ingebrigtsen TS,
    3. Çolak Y, et al.
    Lung function trajectories leading to chronic obstructive pulmonary disease as predictors of exacerbations and mortality. Am J Respir Crit Care Med 2020; 202: 210–218. doi:10.1164/rccm.201911-2115OC
    OpenUrl
  9. ↵
    1. Agusti A,
    2. Noell G,
    3. Brugada J, et al.
    Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med 2017; 5: 935–945. doi:10.1016/S2213-2600(17)30434-4
    OpenUrl
  10. ↵
    1. Whittaker HR,
    2. Bloom C,
    3. Morgan A, et al.
    Accelerated FEV1 decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. Eur Respir J 2021; 57: 2000918. doi: 10.1183/13993003.00918-2020.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Donaldson GC,
    2. Hurst JR,
    3. Smith CJ, et al.
    Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091–1097. doi:10.1378/chest.09-2029
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Rothnie KJ,
    2. Connell O,
    3. Mullerova H, et al.
    Myocardial infarction and ischemic stroke after exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2018; 15: 935–946. doi:10.1513/AnnalsATS.201710-815OC
    OpenUrlPubMed
  13. ↵
    1. Kunisaki KM,
    2. Dransfield MT,
    3. Anderson JA, et al.
    Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med 2018; 198: 51–57. doi:10.1164/rccm.201711-2239OC
    OpenUrlPubMed
  14. ↵
    1. Halpin DM,
    2. Decramer M,
    3. Celli B, et al.
    Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT(R) trial. Lung 2011; 189: 261–268. doi:10.1007/s00408-011-9301-8
    OpenUrlCrossRefPubMed
  15. ↵
    1. Sin DD,
    2. Man SF
    . Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514–1519. doi:10.1161/01.CIR.0000056767.69054.B3
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Thomsen M,
    2. Dahl M,
    3. Lange P, et al.
    Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 982–988. doi:10.1164/rccm.201206-1113OC
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Sarwar N,
    2. Butterworth AS,
    3. Freitag DF, et al.
    Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379: 1205–1213. doi:10.1016/S0140-6736(11)61931-4
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Swerdlow DI,
    2. Holmes MV,
    3. Kuchenbaecker KB, et al.
    The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379: 1214–1224. doi:10.1016/S0140-6736(12)60110-X
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Ridker PM,
    2. Libby P,
    3. MacFadyen JG, et al.
    Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J 2018; 39: 3499–3507. doi:10.1093/eurheartj/ehy310
    OpenUrlPubMed
  20. ↵
    1. Silvestre OM,
    2. Nadruz W Jr.,
    3. Querejeta Roca G, et al.
    Declining lung function and cardiovascular risk: the ARIC study. J Am Coll Cardiol 2018; 72: 1109–1122. doi:10.1016/j.jacc.2018.06.049
    OpenUrlFREE Full Text
  21. ↵
    1. Agusti A,
    2. Faner R
    . Lung function trajectories in health and disease. Lancet Respir Med 2019; 7: 358–364. doi:10.1016/S2213-2600(18)30529-0
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 3 Table of Contents
European Respiratory Journal: 57 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD
Yunus Çolak
European Respiratory Journal Mar 2021, 57 (3) 2004008; DOI: 10.1183/13993003.04008-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD
Yunus Çolak
European Respiratory Journal Mar 2021, 57 (3) 2004008; DOI: 10.1183/13993003.04008-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Sotatercept, haemodynamics and the right ventricle
  • GOLD 2023 streamlines pharmacological treatment
  • The ERS PROFILE.net Clinical Research Collaboration
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society